Phase II study of amonafide in advanced
โ
Kaye Linke; Richard Pazdur; James L. Abbruzzese; Jaffer A. Ajani; Rodger Winn; J
๐
Article
๐
1991
๐
Springer US
๐
English
โ 262 KB
To determine the efficacy of amonafide in patients with advanced, measurable pancreatic adenocarcinoma, 15 patients previously untreated with chemotherapy were entered on a phase II trial. The starting dose was 400 mg/m 2 administered daily over 1 hr for 5 consecutive days repeated every 3 weeks. Be